Showing results (541-550 of 1,842) with videos related to
Sort By:
Pageof 185
Journal of Managed Care & Specialty Pharmacy|March 25, 2022
Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact modelJordan Hinahara, Stuart A Weinzimer, Emilie R Bromley, et al.Journal of Managed Care & Specialty Pharmacy|March 25, 2022
Cost-effectiveness and value of information analyses of Bruton's tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United StatesNeda Alrawashdh, Ali McBride, Marion Slack, et al.Journal of Managed Care & Specialty Pharmacy|March 30, 2022
Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulinEugene E Wright, Daniel C Malone, Jennifer M Trujillo, et al.Journal of Managed Care & Specialty Pharmacy|September 25, 2018
Costs Associated with Productivity Loss Among U.S. Patients Newly Diagnosed with Multiple Myeloma Receiving Oral Versus Injectable ChemotherapyDavid Merola, Candice Yong, Stephen J Noga, et al.Journal of Managed Care & Specialty Pharmacy|August 30, 2018
A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare PopulationAlpesh Amin, Allison Keshishian, Jeffrey Trocio, et al.Journal of Managed Care & Specialty Pharmacy|August 30, 2018
Opioid Analgesics in Georgia Medicaid: Trends in Potential Inappropriate Prescribing Practices by Demographic Characteristics, 2009-2014Jayani Jayawardhana, Amanda J Abraham, Matthew PerriJournal of Managed Care & Specialty Pharmacy|October 9, 2018
Meeting Abstracts - Academy of Managed Care Pharmacy Nexus 2018Journal of Managed Care & Specialty Pharmacy|May 26, 2018
The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare PerspectivesChristopher A Bly, Cliff Molife, Jacqueline Brown, et al.Journal of Managed Care & Specialty Pharmacy|August 31, 2016
Evaluation of Specialty Drug Price Trends Using Data from Retrospective Pharmacy Sales TransactionsRobert Penington, Jo Ann StubbingsJournal of Managed Care & Specialty Pharmacy|September 1, 2016
Initial Medication Adherence in the Elderly Using PACE Claim Reversals: A Pilot StudyDoris A Forestal, Tamar A Klaiman, Andrew M Peterson, et al.Pageof 185